Equillium (EQ) Long-Term Debt Issuances (2019 - 2023)

Equillium's (EQ) quarterly Long-Term Debt Issuances came in at $7.7 million in Q2 2023, up 439.12% on a QoQ basis from $1.4 million in Q1 2023.

Equillium (EQ) Long-Term Debt Issuances (2019 - 2023) Analysis & Trends

Equillium (EQ) has 2 years of Long-Term Debt Issuances data on file, last reported at $7.7 million in Q2 2023.

On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $7.7 million in Q2 2023; TTM through Dec 2023 was $9.1 million, a N/A change from a year earlier, with the FY2023 full-year figure at $9.1 million, up 539.12% from the prior year.
Long-Term Debt Issuances for Q2 2023 stood at $7.7 million, up from $1.4 million in the prior quarter.
Over the last five years, Long-Term Debt Issuances for EQ reached as high as $7.7 million in Q2 2023 and fell as low as -$60000.0 in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Equillium	258.99 Mn	258.99 Mn	-	-

Download Data